Skip to main content

The Delhi High Court granted an ex parte interim injunction restraining the defendants from marketing VARDENAFIL and VARDENAFIL HYDROCHLORIDE in India.

The court noted that the defendants product contained the plaintiff Bayer’s patented pharmaceutical preparation, but without its permission to exploit the same. The defendants’ drugs, though not commercially launched in India, were being exported to other countries.

Bayer initiated legal proceedings in India upon learning that drugs infringing its patent, valid till 2018, had been seized by customs authorities in Latvia.

Bayer Intellectual Property GmbH v Vipro Lifescience and anr.

Most Recent

News & Insights

VIEW ALL
Thought Leadership
Oct 16, 2025

‘First published on Lexology’ By: Safir Anand and Omesh Puri The Office of the Controller General of Patents, Designs, and Trade Marks has issued a

Indian Trade Marks Office issues Office Order – Streamlining Registry Function
News & Updates
Oct 16, 2025

Being a part of the International Trademarks Association (INTA) is always a delight. Here’s how Anand and Anand would be joining forces with INTA on

Team Anand and Anand for INTA
Thought Leadership
Oct 14, 2025

‘First published on Lexology’ By: Safir Anand and Arpita Mukherjee When WeWork faced turmoil globally, leading its U.S. parent company to file for

WeWork India’s NSE Listing: A Lesson in Local Execution Within Global Brands
Thought Leadership
Oct 02, 2025

‘First published on India Business Law Journal’ By: Pravin Anand and Dr. Ajai Garg The fourth industrial revolution, driven by artificial intelligence

Independent AI key to India’s global power